Skip to main content

You are here

Pfizer

Archived Projects

15 Archived Projects

Title	Investigator	Start	End
A Multicenter, Randomized, Double-Blind, Placebo Controlled Trial of a Novel CCR5 Antagonist, UK427,857, for the Treatment of Antiretroviral-Experienced HIV-1-Infected Subjects	Luetkemeyer	3/21/05	2/14/10
A Randomized, Double Blind, Placebo Controlled, Multicenter Study to Evaluate the Efficacy &Safety of Atorvastatin in Patients w/ Clinically Isolated Syndrome & High Risk for Conversion to M.S.	Bluestone	9/1/03	8/30/10
A8851009: A Prospective, Randomized Trial Comparing the Efficacy of Anidulafungin and Voriconazole in Combination to that of Voriconazole Alone When Used For Primary Therapy of Proven or Probable Invasive Aspergillosis		7/15/08	8/31/10
Accelerating and Intensifying Tuberculosis Case Finding in Uganda	Davis	7/1/11	6/30/13
Effects of Maraviroc on HIV-related Kaposi Sarcoma	Maurer	7/1/11	9/30/17
Efficacy and Safety of Eraxis/Ecalta (Anidulafungin) Compared to Cancidas (Caspofungin) in Patients with Candida Deep Tissue Infection: A Phase 4 Study		10/1/10	9/30/12
Exploring the Role of CDK4 and CDK6 in Melanoma Maintenance		6/3/13	6/30/16
International Fellowship Program in Drug Development		10/1/04	12/31/12
Mycotic Ulcer Treatment Trial (MUTT)	Acharya	10/20/09	11/1/13
Pfizer A4001027: Observational Phase Extension	Luetkemeyer	5/13/08	6/30/12
Phase IV Open-Label, Non-comparative Trial of IV Anidulafungin followed by Oral Azole Therapy for the Treatment of Candidemia and Invasive Candidiasis		1/17/08	3/31/10
QB3-UCSF Pfizer Collaboration	Kelly	7/1/08	12/31/16
Rifabutin Based Therapy for Eradication of Staph Carriage in HIV-Infected Individuals with Prior Skin Structure Infections	Chambers	6/4/09	1/1/12
The Use of Nelfinavir During Acute or Early HIV Infection - Safety, Tolerability, Durablilty and Resistance	Hare	8/5/05	5/13/06
ViiV Healthcare A4001098	Luetkemeyer	4/12/11	4/11/16